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Novelty Statement: Measurement of peripheral blood (PB) Wilm's Tumor 1 (WT1)- mRNA expression using a standardized assay represents a practicable approach to sensitively assess 
pretransplant minimal residual disease (MRD) and is applicable in the majority of patients with AML/MDS independent from disease- specific molecular features. Pretransplant PB WT1 
expression enables refined estimation of post- transplant relapse risk and overall survival in patients with AML and MDS. In patients with pretransplant MRD positivity assessed by WT1 
expression, an optimization of peri- /post- transplant management (eg, pretransplant salvage therapy, an intensification of conditioning regimen or prophylactic/pre- emptive treatment 
strategies post- transplant) appears reasonable to overcome the negative prognostic impact of pretransplant MRD. 
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Abstract
Objective: As peripheral blood (PB) Wilm's Tumor 1 (WT1)- mRNA expression is estab-
lished as MRD- marker during conventional AML chemotherapy, impact of pretrans-
plant WT1 expression remains unclear. Therefore, we aimed to assess prognostic 
impact of pretransplant WT1 expression on post- transplant outcome in patients with 
AML/MDS.
Methods: In 64 AML/MDS patients, pretransplant WT1 expression was retrospec-
tively analyzed using a standardized assay offering high sensitivity, specificity, and 
a validated cut- off. Patients were divided into three groups determined by pretrans-
plant remission and WT1 expression. Post- transplant outcome of these groups was 
compared regarding cumulative incidence of relapse (CIR), relapse- free (RFS), and 
overall survival (OS).
Results: Pretransplant forty- six patients (72%) showed hematologic remission, in-
cluding 21 (46%) MRD- negative and 25 (54%) MRD- positive patients indicated by 
WT1 expression, while 18 refractory patients (28%) showed active disease. Two- year 
estimates of post- transplant CIR, RFS, and OS were similar in MRD- positive (61%, 
37%, 54%) and refractory patients (70%, 26%, 56%), but significantly inferior com-
pared with MRD- negative patients (10%, 89%, 90%). After multivariable adjustment, 
pretransplant MRD negativity measured by WT1 expression retained its prognostic 
impact on CIR (P = .008), RFS (P = .005), and OS (P = .049).
Conclusions: PB WT1 expression represents a useful method to estimate pretrans-
plant MRD, which is highly predictable for post- transplant outcome and may help 
improving peri- transplant management in AML/MDS patients.
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1  | INTRODUC TION
Allogeneic hematopoietic stem cell transplantation (allo- HSCT) is a 
curative treatment approach for many patients with acute myeloid 
leukemia (AML) and myelodysplastic syndromes (MDS). In patients 
with AML, allo- HSCT is most effective when performed in complete 
remission (CR), which is usually achieved after intensive chemother-
apy (CTX).1,2 The role of pretransplant cytoreduction in advanced 
MDS or AML derived from MDS (sAML) is still a matter of debate,3- 6 
but those 20% to 50% of patients, who achieve remission either 
after CTX or hypomethylating agents (HMA), have a good chance to 
achieve long- term survival. Still, even in the absence of morpholog-
ically detectable disease at the time of transplant, relapse remains 
the main cause of treatment failure, suggesting that conventional 
morphology is incapable to detect clinically relevant amounts of 
malignant cells, which subsequently drive post- transplant relapse.1,7 
In accordance with this, several groups have shown in general that 
the presence of submicroscopic levels of leukemia (ie, measurable 
residual disease, MRD) detected by multiparametric flow cytometry 
(MFC), PCR- , or NGS- based techniques at the time of transplantation 
offers prognostic information in patients undergoing allo- HSCT in 
hematologic remission.8- 19 However, the following methodological 
and biological aspects limit their use in clinical routine: (1) molecular 
aberrations suitable for sensitive MRD monitoring are only present 
in subgroups of patients and/or instable during the course of dis-
ease; (2) lack of reproducible standardized assays and/or high tech-
nical and resource- consuming efforts; (3) the need for bone marrow 
(BM) as optimal sample source. In contrast, we and other have 
demonstrated that measurement of Wilms Tumor 1 (WT1)- mRNA 
expression offers several of these advantageous properties, as it is 
present in about 80 to 90% of patients with AML and advanced MDS 
and can be quantitatively measured in peripheral blood (PB) using a 
standardized assay with high sensitivity and specificity.20- 24 In the 
current retrospective analysis, we aimed to determine the prognos-
tic impact of pretransplant MRD detected by PB WT1- mRNA ex-
pression on post- transplant outcome in patients with AML or MDS 
undergoing allo- HSCT in hematologic remission.
2  | METHODS
2.1 | Study Design
This retrospective analysis included 64 patients with AML (n = 50) 
without recurrent genetic abnormalities, advanced MDS, or chronic 
myelomonocytic leukemia (CMML) (n = 14), who were allografted at 
our center between March 2013 and January 2020 either in hema-
tologic CR (n = 46, 72%) or with active disease after being refractory 
to chemotherapy (n = 18, 28%). Further inclusion criteria were PB 
WT1- mRNA overexpression at diagnosis and available information 
about PB WT1- mRNA expression level before transplantation. Post- 
transplant outcome in terms of overall (OS) and relapse- free survival 
(RFS) as well as relapse incidence (CIR) and non- relapse mortal-
ity (NRM) were compared between patients with MRD- positive 
(CRMRD+) and MRD- negative (CRMRD- ) CR prior transplant assessed 
by PB WT1- mRNA expression status as well as 18 refractory patients 
with morphological evidence of disease at transplantation. All pa-
tients gave written informed consent according to the Declaration 
of Helsinki, and the analysis was approved of the institutional review 
board (approval numbers: 3973, 3768 and 3541).
2.2 | Quantitative assessment of peripheral blood 
cell WT1- mRNA expression
Quantitative assessment of WT1- mRNA expression in PB mononu-
clear cells was performed using the Ipsogen® WT1 ProfilQuant® 
Kit according to the manufacturers' instructions with technical 
and quality settings as previously described.23 This plasmid- based, 
standardized, ELN- certified assay offers a validated cut- off level of 
50 WT1 copies/104 ABL copies in PB to distinguish between normal 
and overexpression of WT1- mRNA.20 This cut- off was established 
and validated using 620 diagnostic and 129 follow- up samples from 
504 AML patients and 118 peripheral blood samples from healthy 
volunteers in a systemic evaluation of nine published and in- house 
PCR- based assays in a network of 11 laboratories. As another ad-
vantage, this assay includes specific plasmids, primers, and probes, 
which enables stable and checkable performance of the assay and 
exact quantification of WT1- mRNA expression within each sample 
via standard curve. These properties make results and the specific 
cut- off reproducible and comparable between different laboratories 
when using this assay. All patients with CR prior transplant were 
categorized for post- transplant outcome analyses based on this vali-
dated cut- off level into those with normalized (defined as <50 WT1 
copies/104 ABL copies) PB WT1- mRNA expression representing 
CRMRD-  and those with WT1- mRNA overexpression (defined as >50 
WT1 copies/104 ABL copies) reflecting CRMRD+. The results from 
MRD analyses were available to the transplant team.
2.3 | Definitions and Response Criteria
Remission status prior transplant and conditioning intensity was de-
fined as previously reported.2,25- 28 Furthermore, depth of remission 
regarding MRD was defined as described above.29 Post- transplant 
hematologic relapse was defined as ≥5% BM blasts, detection of 
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blasts in PB, and/or extramedullary disease. Molecular relapse after 
allo- HSCT was defined as presence of disease- specific cytogenetic 
aberrations, reoccurrence of known mutations in at least 1% of 
reads, a decrease in donor chimerism <95%, evidence of a mixed 
XY- FISH of >4% residual recipient cells, or an increase of PB WT1- 
mRNA expression above the cut- off of 50 copies per 104 ABL copies 
detected at two separate time points during an interval of 14 days 
and in absence of any criterion defining hematologic relapse. Both 
hematologic and molecular relapse were appraised as event for CIR 
and RFS.
2.4 | Statistical analyses
Data lock for this analysis was June 1, 2020. For categorical vari-
ables, frequencies were given and differences were estimated apply-
ing cross tabulation and Fisher's exact test. For continuous variables, 
medians (ranges) were given and the Mann- Whitney test was used 
to detect differences. OS was calculated as date from allo- HSCT to 
death from any cause or last follow- up in survivors. RFS was defined 
as time from allo- HSCT until (i) molecular or hematologic relapse or 
(ii) death with those censored at last contact who were alive and had 
not experienced relapse until then. Both OS and RFS were estimated 
using Kaplan- Meier method, and log- rank test was used for uni-
variate comparisons. Relapse incidence and non- relapse mortality 
(NRM) were considered as competing risks and calculated using cu-
mulative incidence (CI) estimates employing Gray test for univariate 
comparisons. Multivariate analysis was performed using a multiple 
Cox regression model with a step- wise backward procedure and in-
cluded only variables influencing outcome in univariate analysis with 
a P- value <.1. For relapse incidence and NRM variables, multivariate 
analyses have to be interpreted as a cause- specific hazards model. In 
all analyses, a P- value <.05 was considered to be statistically signifi-
cant. Statistical analyses were performed using GraphPad Prism® 
5.01 (GraphPad Software Inc, La Jolla, USA), SPSS Statistic for 
Windows (SPSS Inc Chicago, IL), and R 4.0.0.
3  | RESULTS
3.1 | Patient Characteristics
For this analysis, we identified 46 patients with MDS/MPN (n = 8, 
17%), sAML (n = 14, 30%), therapy- related (n = 3, 7%), or de novo 
AML (n = 21, 46%) with PB WT1- mRNA overexpression (median 
2187.6, range 76 to 26 433.1 WT1 copies per 104 ABL copies) at 
diagnosis, who underwent first allo- SCT in hematologic CR at our 
institution between March 2013 and January 2020. Besides WT1- 
mRNA overexpression at diagnosis, these patients had no molecu-
lar marker such as NPM1 or other recurrent genetic abnormalities 
suitable for sensitive PCR- based MRD monitoring. As indicated in 
Table S1, individual patients exhibited mutations in genes such as 
FLT3, DNMT3A, or ASXL1. However, these molecular markers are 
not optimal for MRD monitoring due to instability during course of 
disease, lack of sensitive assays in clinical routine, and/or associa-
tion with clonal hematopoiesis. Detailed information regarding pa-
tients and transplant characteristics is summarized in Tables 1 and 
2. Patients had achieved first (n = 44, 96%) or second CR (n = 2, 4%) 
after treatment with a median of 2 (range: 1- 5) cycles of intensive 
CTX (n = 39, 85%) or after a median of 2 (range: 1- 7) cycles of HMA 
(n = 7, 15%). Of these 46 patients, 21 (46%) were MRD- negative 
indicated by normalized PB WT1- mRNA values (<50 WT1 copies 
per 104 ABL copies; median 7.3, range 0 to 42.6 WT1 copies per 
104 ABL copies), while 25 patients (54%) still showed WT1- mRNA 
overexpression in PB (≥50 WT1 copies per 104 ABL copies; median 
149, range 52 to 4 002.9 WT1 copies per 104 ABL copies) thus being 
MRD- positive. The majority of patients received peripheral blood 
stem cells (n = 43, 93%) from a HLA- matched unrelated donor 
(n = 27, 59%) after reduced intensity conditioning (RIC, n = 30, 
65%), whereas 16 patients (35%) underwent allo- HSCT after my-
eloablative conditioning according to the definitions determined by 
Bacigalpuo and colleagues.27 Further details regarding conditioning 
regimen of the entire study population including refractory patients 
are displayed in Table S2. Median time between diagnosis and allo- 
HSCT was 3.7 months (range, 0.7 to 37.8) and was similar between 
CRMRD+ patients (median 3.6 months, range 0.7 to 18.6 months) 
and CRMRD-  patients (median 3.7 months, range 2.2 to 37.8 months, 
P =.772). Median time between MRD assessment and allo- HSCT 
was 21 days (range, 4 to 70) and also comparable between CRMRD+ 
patients (median 21 days, range 7- 69) and CRMRD-  patients (median 
20 days, range 4 to 70, P =.674). Furthermore, with the exception 
of a significantly higher frequency of an abnormal karyotype, there 
were no differences between patients with CRMRD+ and CRMRD-  re-
garding common patient- , disease- , or transplant- related factors 
(Table 2). Eighteen additional patients with AML, MDS, or CMML 
were primary refractory to induction chemotherapy and underwent 
allo- SCT during the same time- period with active hematologic dis-
ease. Baseline characteristics of these 18 patients were comparable 
to the 46 patients transplanted in CR (Table 2) including the fact that 
with except for WT1- mRNA overexpression they neither exhibited a 
molecular marker suitable for sensitive PCR- based MRD monitoring.
3.2 | Outcome after allo- HSCT
A total of 14 deaths, 21 relapses, and 2 NRM events contributed 
to the probability estimates for OS, RFS, relapse, and NRM strati-
fied by MRD status in the 46 patients with CR at transplant. After a 
median post- transplant follow- up period of 33.7 months (range: 2.8- 
67.3 months), the 2- year OS, RFS, CIR, and NRM rate of these 46 pa-
tients with hematologic CR was 68% [95% CI: 51%- 80%], 58% [95% 
CI: 41%- 72%], 41% [95% CI: 27%- 58%], and 4% [95% CI: 1%- 17%], 
respectively (Figure 1). As indicated in Figure 2, in univariate analy-
sis, the estimates for OS (two year probability: 54% vs 90%, log- rank 
P =.03), RFS (two year probability: 37% vs 89%, log- rank P <.01), and 
CIR (two year probability: 61% vs 10%, Gray test P <.01) significantly 
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differed between patients with CRMRD+ and CRMRD-  suggesting that 
pretransplant MRD status assessed by WT1- mRNA expression ena-
bles risk stratification of patients undergoing allo- HSCT in hema-
tologic CR. We then compared the outcome of patients receiving 
allo- HSCT in hematologic CR with the cohort of 18 patients with 
active disease at allo- HSCT. Of note, the outcome of CRMRD+ pa-
tients in terms of OS, RFS, and CIR did not differ with the outcome of 
refractory patients (OS (two year probability: 54% vs 56%, log- rank 
P =.94), RFS (two year probability: 37% vs 26%, log- rank P =.27), 
and CIR (two year probability: 61% vs 70%, Gray test P =.32), while 
CRMRD-  patients had a significantly better outcome (Figure 2).
TA B L E  1   Patients demographics and transplant characteristics
Remission status prior 
allo- HSCT CR (n = 46)
refractory 
(n = 18)
PCharacteristic No. % No. %
Age, median (range), y 58 (21- 73) 59 (27- 69) .61
Gender .78
Male 25 54 11 61
Female 21 46 7 49
WHO 2016 diagnosisa 
AML
AML- MRC 14 30 7 39 .56
t- MN 3 7 0 0 .55
AML NOS 20 43 5 28 .27
Myeloid sarcoma 1 2 0 >.99
MDS/MPN
MDS- EB2 6 13 5 28 .27
CMML 2 4 1 6 >.99
Karyotype
Normal 22 48 7 39 .58
Aberrant 24 52 11 61
Complex 10 22 7 39 .21
ELN cytogenetic/molecular genetic riskb 
Favorable 0 0 0 0 >.99*
Intermediate 15 39 5 41
Adverse 22 58 7 58
Missing 1 3 0 0
IPSS- R cytogenetic Riskc 
Very good/good 0 0 2 40 .08# 
Intermediate 1 17 2 40
Poor/very poor 5 83 1 20
Disease Status at allo- HSCTb/d
CR1 44 96 - 
CR2 2 4 - 
MRD Status prior transplante 
CRMRD+ 25 54 18 100
CRMRD- 21 46 - - 
Conditioningf 
Myeloablative 16 35 7 39 .78
Dose- reduced 30 65 11 61
HCT- CI
Low 27 59 11 61 >.99
Int/high 19 41 7 39
Donor Type
Matched related 9 20 5 28 .51
Matched unrelated 27 58 9 50 .58
Mismatched related 1 2 0 0
(Continues)
Remission status prior 
allo- HSCT CR (n = 46)
refractory 
(n = 18)
PCharacteristic No. % No. %
Mismatched 
unrelated
9 20 4 22 >.99
Haploidentical 0 0 0 0
Immunosuppression
MMF + CSA 10 22 5 28 .74
MMF + FK506 36 78 13 72
In vivo T- cell depletion
Yes 36 78 13 72 .74
No 10 22 5 28
Graft source
PBSC 43 93 18 100 .55
BM 3 7 0 0
Abbreviations: Allo- HSCT, allogeneic hematopoietic stem cell 
transplantation; AML, acute myeloid leukemia; AML- MRC, acute 
myeloid leukemia with myelodysplasia related changes; AML NOS, 
acute myeloid leukemia not otherwise specified; BM, bone marrow; 
CMML, chronic myelomonocytic leukemia; CR, complete remission; 
CSA, ciclosporin A; EB2, excess blasts 2; ELN, european leukemia net; 
FK506, Tacrolimus; HCT- CI, hematopoietic cell transplantation- specific 
comorbidity index; IPSS- R, revised international prognostic scoring 
system; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; 
MPN, myeloproliferative neoplasia; MRD, minimal residual disease; no., 
number; P, P- value; PBSC, peripheral blood stem cells; t- MN, therapy- 
related myeloid neoplasm; WHO, world health organization; WT1, 
Wilm's Tumor 1; y, years.
aaccording to Arber et al Blood 2016.25
baccording to ELN- criteria, Döhner et al Blood.2
cacoording to IPSS- R, Greenberg et al Blood 2012.28
daccording to Cheson et al Blood 2006.26
eregarding WT1- mRNA expression (CRMRD+ = ≥ 50 WT1 copies/10
4ABL 
copies; CRMRD-  = <50 WT1 copies/10
4ABL copies).
faccording to Bacigalupo et al BBMT 2009.27
*No significant differences regarding frequency of favorable and 
intermediate compared to adverse ELN risk categories among patients 
with hematologic CR prior transplant and refractory patients.
#No significant differences regarding frequency of very good/good and 
intermediate compared to poor and very poor IPSS- R cytogenetic risk 
categories among patients with hematologic CR prior transplant and 
refractory patients.
TA B L E  1   (Continued)
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Focusing on other patient- , disease- , or transplant- related pa-
rameters, we found that in addition to the MRD status, the pres-
ence of a complex karyotype, high- risk genetics, and the use of a 
related donor were associated with a shorter OS in univariate anal-
ysis. A complex KT was also the only factor besides MRD status, 
which showed an impact on RFS and relapse incidence in univariate 
analysis (Table S3). Due to the low number of events (n = 4), no pa-
rameter associated with NRM could be ascertained.
In multivariate analyses, pretransplant MRD negativity mea-
sured by WT1- mRNA expression was associated with longer RFS, 
lower relapse incidence, and longer OS than MRD positivity. While 
no other parameter besides MRD status influenced RFS and relapse 
TA B L E  2   Comparison of patient- and transplant- related characteristics according to MRD status prior transplant assessed by WT1- mRNA 




No. of patients 46 (100%) 25 21
Follow- up, median (range), mo 33.7 (2.8- 67.3) 37.4 (2.8- 59.4) 26.3 (2.9- 67.3) .77
Age, median (range), y 58 (21- 73) 61 (24- 69) 56 (21- 52) .14
Gender >.99
Male 22 (48%) 12 10
Female 24 (52%) 13 11
WHO 2016 diagnosisa 
AML
AML- MRC 14 (30%) 10 4 *, &, §
De novo AML (therapy rel AML, AML NOS, Myeloid sarcoma) 24 (52%) 10 14
MDS/MPN
MDS- EB2 6 (13%) 4 2
CMML 2 (4%) 1 1
Karyotype
Normal 22 (48%) 8 14 .04
Aberrant 24 (52%) 17 7 .31
Complex 10 (22%) 7 3
Cytogenetic risk categoryb 
Low/int 16 (35%) 7 9 .36
High 27 (59%) 16 11
Missing 3 (7%) 2 1
WT1- mRNA expression at diagnosis, median (range) 2188 (74- 26433) 2140 (94- 19547) 2397 (74- 26433) .76
FLT3- ITD mutation status
mut and high ratio 8 (17%) 3 5 .45
wt or mut and low ratio 31 (67%) 17 14
Missing 7 (15%) 5 2
Time to between diagnosis to allo- HSCT, months, median (range) 3.7 (0.7- 37.8) 3.6 (0.7- 18.8) 3.7 (2.2- 37.8) .74
HCT- CI
Low 27 (59%) 12 15 .14
Int/high 19 (41%) 13 6
Conditioningc 
Myeloablative 16 (35%) 7 9 .36
Dose- reduced 30 (65%) 18 12
Donor Type
Related 10 (22%) 5 5 >.99
Unrelated 36 (78%) 20 16
(Continues)
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incidence, the use of a related donor was confirmed as predictor for 
shorter OS (Table 3).
3.3 | Relapse pattern and salvage therapy
Of the 46 patients with hematologic remission at allo- SCT, twenty- 
one (46%) experienced either molecular (n = 8, 38%) or hemato-
logic (n = 13, 62%) relapse after a median of 11 months (range, 
1- 66 months). This included 18 (86%) of CRMRD+ patients and 3 
(14%) of CRMRD-  patients (Table S4). Of the 25 CRMRD+ patients, 24 
achieved MRD negativity after transplant, while one patient did 
not achieve MRD negativity and immediately showed disease pro-
gression. Of the remaining 17 relapses within the CRMRD+ cohort, 
14 showed rise of WT1- mRNA expression at the time of relapse, 
while 3 patients remained below the validated cut- off of 50 WT1- 
mRNA copies, thus being in excellent agreement with our previ-
ous results.23 All 3 patients in the CRMRD-  cohort, who relapsed 
after allo- SCT, showed rise of WT1- mRNA expression at relapse 
(Figure S1). Of interest, the time to relapse did not differ between 
CRMRD+ patients and those relapsing patients, who had undergone 
allo- HSCT with active hematologic disease (median time 3.8 months 
vs 4.3 months, P =.55). Nineteen of the 21 relapsing patients (90%) 
received a salvage therapy consisting of HMA and donor lympho-
cyte infusions (DLI), which induced CR in 9 of them (47%), while the 
2 other patients received radiotherapy and DLI or best supportive 
care, respectively. This also includes all 8 patients with molecular 
relapse. All of them were treated with HMA at the stage of molecu-
lar relapse, which led to CR in 5 (63%) of them.
4  | DISCUSSION
The results from this analysis show that measurement of PB WT1- 
mRNA expression using an ELN- certified assay enables determina-
tion of MRD in patients with hematologic remission prior transplant, 
F I G U R E  1   Post- transplant outcome of 46 patients receiving allogeneic transplantation in hematologic complete remission. Figure 1 
represents outcome in terms of (A) cumulative incidence of relapse and non- relapse mortality (dotted line), (B) relapse- free, and (C) overall 





Matched 36 (78%) 20 16 >.99
Mismatched 10 (22%) 5 5
Abbreviations: Allo- HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; AML NOS, acute myeloid leukemia not 
otherwise specified; AML- MRC, acute myeloid leukemia with myelodysplasia related changes; BM, bone marrow; CMML, chronic myelomonocytic 
leukemia; CR; complete remission; EB2, excess blasts 2; ELN, european leukemia net; HCT- CI, hematopoietic cell transplantation- specific comorbidity 
index; IPSS- R, revised international prognostic scoring system; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasia; MRD, minimal 
residual disease; mut, mutation; no., number; PBSC, peripheral blood stem cells; rel, related; WHO, world health organization; wt, wildtype; WT1, 
Wilm's Tumor 1; y, years.
aaccording to Arber et al Blood 201625
bfor MDS IPSS- R risk cytogenetics were applied (Greenberg et al Blood 2012,28 ) and very good, good, and intermediate risk categories were assigned 
to low/intermediate group, whereas poor and very poor risk categories were included into high- risk group; for AML ELN risk cytogenetics were used 
(Döhner et al Blood 2017, (2)) and favorable and intermediate risk categories were assigned to low/intermediate risk group, whereas adverse risk 
category was included into high- risk group.
caccording to Bacigalupo et al BBMT 2009.27
#regarding WT1- mRNA expression (CRMRD+ = ≥ 50 WT1 copies/10
4ABL copies; CRMRD-  = < 50 WT1 copies/10
4ABL copies).
*No significant differences regarding the frequency of AML diagnosis compared to MDS/MPN diagnosis among the CRMRD+ and CRMRD-  group (P =.71).
&No significant differences regarding the frequency of MDS/MPN/sAML diagnosis compared to diagnosis of de novo AML among the CRMRD+ and 
CRMRD-  group (P =.09).
§No significant differences regarding the frequency of MDS diagnosis compared to diagnosis of sAML among the CRMRD+ and CRMRD-  group (P >.99).
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who do not carry another marker suitable for MRD monitoring in 
clinical routine, and thereby facilitates prediction of post- transplant 
relapse and outcome.
The finding that the presence of MRD prior allogeneic trans-
plantation in patients with AML and MDS is associated with higher 
relapse risk and poorer survival after transplant is not new. This has 
already been demonstrated for the use of MFC,8- 11 PCR- based anal-
yses in molecular defined subgroups as exemplified in NPM1- mutant 
AML13,14 and NGS.18,19 Thus, our results obtained by measurement 
of PB WT1- mRNA expression are in agreement with these above 
mentioned methods as well as with studies regarding WT1- mRNA, 
which employed non- standardized in- house assays or used BM as 
sample source.30,31 However, determination of WT1- mRNA expres-
sion may have some advantages over the above mentioned meth-
ods: Molecular markers approachable by sensitive PCR assays such 
as NPM1 (~25%) or core- binding factor aberrations (~10%) are only 
present in subgroups of patients.32 Furthermore, markers such as 
FLT3 mutations are instable during the course and therefore subop-
timal and not recommended for MRD monitoring.29,33 In contrast, 
WT1- mRNA overexpression is found in 80 to 90% of patients with 
AML and advanced MDS as well as stable during the course20- 24 
and consequently recommended if no other suitable marker is 
F I G U R E  2   Post- transplant outcome of patients depending on MRD status assessed by PB WT1- mRNA expression. Figure 2 represents 
outcome in terms of (A) cumulative incidence of relapse, (B) relapse- free, and (C) overall survival for patients with pretransplant CRMRD-  
(n = 21, green line), CRMRD+ (n = 25, orange line), and for those patients being refractory to salvage therapy prior transplant (n = 18, red line)
Variable






P- value HR (95% CI)
Diagnosis
MDS/MPN/sAML - - ns
vs de novo AML
Karyotype
Complex ns ns ns
vs not complex
MRD status prior Tx# 
CRMRD+ <0.01 <0.01 0.05
vs CRMRD- 5.3 (1.6- 18.4) 5.8 (1.7- 19.7) 4.5 (1.0- 20.2)
Donor - - 
Related 0.03
vs unrelated 3.4 (1.1- 10.2)
Abbreviations: AML, acute myeloid leukemia; CR, complete remission; HR, hazard ratio; MDS, 
myelodysplastic syndrome; MPN, myeloproliferative neoplasia; MRD, minimal residual disease; 
ns, not significant; OS, overall survival; RFS, relapse- free survival; sAML, secondary AML; Tx, 
transplant; y, years; “- ” means not applicable.
#Regarding WT1- mRNA expression (MRD+ = ≥50 WT1 copies/104ABL copies; MRD- = <50 WT1 
copies/104ABL copies).
TA B L E  3   Impact of clinical 
parameters on outcome after allogeneic 
transplantation for MDS/MPN and AML— 
multivariate analysis
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available.29 Besides this broad applicability, the availability of a 
standardized assay with a reproducible cut- off value and an assay- 
given sensitivity of 1:104 are another advantage of WT1- mRNA 
monitoring, especially in comparison with MFC. Error- corrected 
NGS approaches overcome some of these limitations, as they offer 
high sensitivity and broad applicability if several markers are used in 
each patient.18,19 Nevertheless, biological aspects have to be con-
sidered and may hamper interpretation of results from NGS- based 
approaches. In detail, persistence of mutations in genes such as 
DNMT3A, TET2, and ASXL1 (so called DTA mutations) may be as-
sociated with preexisting clonal hematopoiesis and did not seem to 
have prognostic implications post- transplant outcome.18,19 In other 
cases, persistence of these mutations may also be a consequence of 
persistence in differentiated cells or germ line origin. Furthermore, 
high technical and resource- consuming demands as reflected by a 
realistic turnaround time of 2- 3 weeks have limited the wide use of 
NGS in clinical routine so far.18 In further support of its practicabil-
ity, the turnaround time for WT1- mRNA measurement in our routine 
is 4 days (range: 2- 7 days, data not shown). Finally, in contrast to 
the other MRD methods, WT1- mRNA expression can be sensitively 
measured in PB thereby enabling frequent monitoring with sus-
tained patient comfort.
The results from our analysis do not only indicate that measure-
ment of PB WT1- mRNA expression is a practicable and valuable ap-
proach to measure MRD and to estimate post- transplant relapse risk 
and survival. They also point toward two other important aspects: (1) 
the outcome in terms of OS, RFS, and relapse incidence as well as the 
time to relapse in patients with hematologic remission, but detect-
able MRD (CRMRD+) is as worse as the outcome of those refractory 
patients with hematologic evidence of disease. This suggests that 
the presence of MRD is not only a quantitative marker reflecting 
low detectable disease burden, but in particular also a biological 
property of the leukemic cells and a qualitative indicator of an intrin-
sic disease resistance. (2) This triggers the question how we should 
therapeutically address the issue of MRD positivity prior transplant 
in our patients in the future. One option may be the incorporation 
of novel compounds such as CPX- 35134 or venetoclax- based combi-
nations35 either as first- line therapy to induce higher rates of MRD 
negativity or as salvage therapy in MRD- positive patients prior 
transplant. Secondly, intensification of the conditioning regimen if 
feasible may also help to overcome the negative prognostic impact 
of MRD, as recently demonstrated.19 Finally, prophylactic or pre- 
emptive treatment strategies after transplantation, for example dis-
continuation of immunosuppression and/or DLI,36 hypomethylating 
agents,37,38 or FLT3 inhibitors39,40 may also reduce relapse risk and 
improve outcome of MRD- positive patients. The latter may explain 
why in our analysis the presence MRD prior transplant was asso-
ciated with higher relapse incidence and lower RFS, but only with 
borderline significance with lower OS in multivariate analysis, since 
7 CRMRD+ patients (=39%) relapsing after allo- SCT could be success-
fully treated with HMA and DLI.
In summary, measurement of PB WT1- mRNA expression with 
a standardized assay is a practicable and efficient approach to 
sensitively assess MRD prior transplant, which is applicable in the 
majority of patients with AML and MDS independent from the mo-
lecular profile, enables refined estimation of relapse risk and sur-
vival, and may help to optimize transplantation and post- transplant 
management.
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